Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 6/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.46 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28627823 | 0.81 | CYP1A2 (0.40) | NPSR1TSHRALDH1A1MAPTKMT2A | |
| SCHEMBL13548854 | 0.78 | GPR3 (0.55) | PRNPRXFP1NPSR1TSHRUSP2 | |
| SCHEMBL11735484 | 0.78 | NPSR1 (0.46) | PRNPRXFP1NPSR1TSHRUSP2 | |
| SCHEMBL31391449 | 0.77 | RXFP1 (0.44) | PRNPRXFP1NPSR1TSHRUSP2 | |
| SCHEMBL3949183 | 0.77 | MAOA (0.47) | PRNPRXFP1NPSR1TSHRUSP2 | |
| SCHEMBL4753647 | 0.77 | DCPS (0.57) | PRNPRXFP1NPSR1TSHRUSP2 | |
| SCHEMBL23775693 | 0.77 | TRPA1 (0.39) | ALDH1A1MAPTKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL20152506 | 0.76 | ADORA2A (0.55) | NPSR1ALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL16838090 | 0.74 | RXFP1 (0.43) | PRNPRXFP1NPSR1TSHRUSP2 | |
| SCHEMBL24995618 | 0.74 | SMN1; SMN2 (0.50) | PRNPRXFP1NPSR1TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123968-A1 | RNA TARGETING COMPOUNDS AND USES THEREOF | RANAR THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-10308617-B2 | Triazole benzamide derivatives and the compositions and methods of treatment regarding the same | An2H Discovery Limited (IE) | 2019-06-04 | — | — | US | disclosed |
| US-20180118697-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2018-05-03 | — | — | US | disclosed |
| WO-2017210694-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | An2H Discovery Limited (IE) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118697-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | PINK1, ATG7, ADRM1 | PRNP 996/4885RXFP1 2989/4885NPSR1 4413/4885 |
| US-10308617-B2 | Triazole benzamide derivatives and the compositions and methods of treatment regarding the same | PINK1, ATG7, ADRM1 | PRNP 996/4885RXFP1 2989/4885NPSR1 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.